Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) had its price target raised by HC Wainwright from $4.00 to $7.50 in a report issued on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the stock.
Unicycive Therapeutics Stock Down 6.4 %
NASDAQ:UNCY opened at $0.57 on Tuesday. The firm has a market capitalization of $59.67 million, a PE ratio of -0.59 and a beta of 2.26. Unicycive Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.60. The stock's 50-day simple moving average is $0.59 and its 200 day simple moving average is $0.57.
Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). On average, analysts anticipate that Unicycive Therapeutics will post -0.23 EPS for the current fiscal year.
Institutional Investors Weigh In On Unicycive Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Walleye Capital LLC bought a new stake in Unicycive Therapeutics during the 3rd quarter worth approximately $2,040,000. Virtu Financial LLC raised its position in Unicycive Therapeutics by 566.8% during the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock worth $30,000 after purchasing an additional 62,881 shares during the last quarter. XTX Topco Ltd acquired a new position in Unicycive Therapeutics during the 3rd quarter worth about $29,000. Northern Trust Corp increased its stake in shares of Unicycive Therapeutics by 142.4% in the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock valued at $46,000 after buying an additional 34,183 shares during the period. Finally, Octagon Capital Advisors LP raised its position in shares of Unicycive Therapeutics by 16.8% during the fourth quarter. Octagon Capital Advisors LP now owns 10,000,000 shares of the company's stock worth $7,942,000 after acquiring an additional 1,441,000 shares during the last quarter. Institutional investors own 40.42% of the company's stock.
About Unicycive Therapeutics
(
Get Free Report)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Unicycive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.
While Unicycive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
